Patients with GRA are characterized by the clinical presentation of early-onset of severe hypertension with the low plasma renin activity (PRA) and mild hypernatremia in which synthetic glucocorticoid administration suppresses this mineralocorticoid excess [41, 42]. This evidence concerns the gene REN and hypertensive disorder.